Relative Bioavailability of BI 44847 in Different Ethnic Groups and Evaluation of Effect of Diet and Acarbose Coadministration on Bioavailability Following Oral Administration of 200 mg BI 44847 in Healthy Male Volunteers

Inclusion Criteria: * Healthy male subjects determined by results of screening * Age 18 - 40 years * Body Mass Index 18 - 25 kg/m2, at least 45 kg * Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice and the local legislation Exclusion Criteria: * Significant gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders as judged by the investigator * Relevant gastrointestinal tract surgery * Diseases of the central nervous system (such as epilepsy, seizures) or psychiatric disorders or relevant neurological disorders * History of relevant orthostatic hypotension, fainting spells or blackouts; systolic blood pressure greater than 140 mm Hg, diastolic blood pressure greater than 90 mm Hg, pulse rate out of 45 to 90 beats per minute * Chronic or relevant acute infections * History of allergy/hypersensitivity (including drug allergies) that are deemed relevant to the trial as judged by the investigator * Intake of drugs with a long half-life (\>24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial * Use within 10 days prior to administration or during the trial of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation * Participation in another trial with an investigational drug within 2 months after a multiple dose study o…